TORL BioTherapeutics Announces Initial Results of Novel Claudin 6 (CLDN6) Targeted Antibody Drug Conjugate (ADC) TORL-1-23 Selected for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Encouraging antitumor activity in heavily pretreated population during dose finding Well tolerated across broad dose range in phase 1 first-in-human study Poster Presentation at ASCO on June 3, 8:00-11:00 a.m. CT LOS ANGELES, June 1, 2023 /PRNewswire/ — TORL BioTherapeutics LLC (“TORL…